This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1 M Egger , B Hirschel , P Francioli , (1997) Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 315, 1194–1199.
2 FJ Palella Jr, KM Delaney , AC Moorman , (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338, 853–860.
3 PP Sendi , HC Bucher , T Harr , (1999) Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. Aids 13, 1115–1122.
4 A Carr , K Samaras , S Burton , (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51–F58.
5 A Carr , K Samaras , DJ Chisholm , (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351, 1881–1883.
6 JH Stein , MA Klein , JL Bellehumeur , (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104, 257–262.
7 UH Iloeje , Y Yuan , G L'Italien , (2005) Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 6, 37–44.
8 I Sudano , LE Spieker , G Noll , (2006) Cardiovascular disease in HIV infection. Am Heart J 151, 1147–1155.
9 E Bernasconi , K Boubaker , C Junghans , (2002) Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 31, 50–55.
10 A Carr , S Emery , M Law , (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361, 726–735.
11 RM Blümer , MG van Vonderen , J Sutinen , (2008) Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 22, 227–236.
12 GM Behrens , AR Boerner , K Weber , (2002) Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110, 1319–1327.
13 SD Fisher , TL Miller & SE Lipshultz (2006) Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 185, 1–11.
14 C Hadigan , S Borgonha , J Rabe , (2002) Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51, 5.
15 DN Reeds , B Mittendorfer , BW Patterson , (2003) Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 285, E490–E497.
16 A Balasubramanyam , RV Sekhar , F Jahoor , (2004) Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: A model of ‘systemic steatosis’. Curr Opin Lipidol 15, 59–67.
17 KN Frayn , SW Coppack , BA Fielding , (1995) Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization. Adv Enzyme Regul 35, 163–178.
18 K Evans , GC Burdge , SA Wootton , (2002) Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51, 2684–2690.
19 K Evans , GC Burdge , SA Wootton , (2007) Tissue-specific stable isotope measurements of postprandial lipid metabolism in familial combined hyperlipidaemia. Atherosclerosis 197, 164–170.
21 JH Stein , MA Merwood , JB Bellehumeur , (2005) Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler Thromb Vasc Biol 25, 399–405.
22 JP van Wijk , MC Cabezas , EJ de Koning , (2005) In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy. J Clin Endocrinol Metab 90, 3575–3582.
23 JL Murphy , A Jones , S Brookes , (1995) The gastrointestinal handling and metabolism of [1-13C]palmitic acid in healthy women. Lipids 30, 291–298.
27 GC Burdge , AE Jones , SM Frye , (2003) Effect of meal sequence on postprandial lipid, glucose and insulin responses in young men. Eur J Clin Nutr 57, 1536–1544.
28 C Grunfeld , M Pang , W Doerrler , (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74, 1045–1052.
30 RV Sekhar , F Jahoor , AC White , (2002) Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 283, E332–E337.
31 DP Kotler , G Ionescu , JA Johnson , (2003) Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis 37, Suppl. 2, S47–S51.
32 L Baril , I Beucler , MA Valantin , (2001) Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS 15, 415–417.
33 W Khovidhunkit , MS Kim , RA Memon , (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45, 1169–1196.
34 MA den Boer , JF Berbée , P Reiss , (2006) Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol 26, 124–129.
35 PJ Randle (1998) Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14, 21.